Skip to main content
See every side of every news story
Published loading...Updated

Amgen to invest $600M in new US center; Sanofi drug for ITP approved

Amgen's $600 million investment aims to enhance advanced automation and digital innovation for serious disease therapies, supported by recent U.S. corporate tax cuts.

The new "science and innovation center" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources are Center
50% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Tuesday, September 2, 2025.
Sources are mostly out of (0)
News
For You
Search
BlindspotLocal